Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MERLIN trial of ORBCEL-C in autoimmune liver disease
ISRCTN73586959Phase 2Active, not recruiting
- Sponsor
- University of Birmingham
- Start
- Dec 2017
- Modality
- Stem Cell Therapies → Cell Therapies
01
Overview
Phase 2, open-label trial of Orbcel-C in Primary Sclerosing Cholangitis (PSC) and autoimmune hepatitis (AIH) (2 cohorts), sponsored by University of Birmingham. Primary endpoints: Highest safe dose, Safety and tolerability at highest safe dose and 2 more. Started Dec 2017; status: active, not recruiting.
02
Drugs
Orbcel-C
03
Conditions
Primary Sclerosing Cholangitis (PSC)autoimmune hepatitis (AIH)
Beyond the preview
Go deeper on ISRCTN73586959.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN73586959.